trending Market Intelligence /marketintelligence/en/news-insights/trending/5noIlmx8uy1T6reqJ17d9A2 content esgSubNav
In This List

Endo settles opioid claims with Oklahoma for $8.75M

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Endo settles opioid claims with Oklahoma for $8.75M

Endo International PLC has reached an $8.75 million settlement with Oklahoma officials to resolve the generics and specialty pharmaceutical company's role in ongoing litigation over the U.S. opioid epidemic.

Malvern, Pa.-based Endo and its subsidiaries, Endo Pharmaceuticals Inc. and Par Pharmaceutical Inc., agreed with the state to settle all claims and resolve the investigation into the company's involvements in the opioid abuse crisis, according to a Jan. 10 press release. The company's senior leadership reached the agreement with Oklahoma Attorney General Mike Hunter and staff.

The settlement does not include an admission of any wrongdoing on the part of Endo.

A number of companies have reached settlements with states to resolve claims that certain marketing practices fueled the opioid epidemic, which kills about 200 Americans each day.